FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to the field of pharmaceutics and deals with a pharmaceutical composition, which contains feline erythropoietin as an active ingredient, to which two or more polyethyleneglycol molecules with a non-branched chain are attached, with a water-soluble long-chain molecule having the molecular weight, constituting not less than 30 kDa and producing the haemopoietic effect. A haemopoietic medication and a medication for the treatment of anaemia are based on the said composition.
EFFECT: group of inventions provides the haemopoietic effect, which lasts for not less than seven days, when introduced to humans and/or animals.
8 cl, 4 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2281116C2 |
| CONJUGATES OF ERYTHROPOIETIN AND POLYETHYLENE GLYCOL, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHOD FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISTURBANCES AND METHOD FOR PREPARING CONJUGATE OR COMPOSITION | 2000 |
|
RU2232163C2 |
| NEW METHOD FOR OBTAINING LONG-ACTING DRUG CONJUGATE BY PRODUCING INTERMEDIATE | 2019 |
|
RU2805873C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING Fc-REGION OF IMMUNOGLOBULIN AS CARRIER | 2004 |
|
RU2352583C2 |
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| CONJUGATED FACTOR VIII MOLECULES | 2009 |
|
RU2573587C2 |
| CONJUGATE OF GLYCOPROTEIN, POSSESSING ERYTHROPOIETIN ACTIVITY, WITH POLY-1,4-ETHYLENEPIPERAZINE N-OXIDE DERIVATIVES (VERSIONS), PHARMACEUTICAL COMPOSITION AND METHOD OF CONJUGATE OBTAINING | 2013 |
|
RU2556378C2 |
| VERSIONS OF ERYTHROPOETINE | 2006 |
|
RU2430162C2 |
| NEW VERSION OF EXENDIN OR ITS CONJUGATE | 2010 |
|
RU2528734C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
